Analysts Have Conflicting Sentiments on These Healthcare Companies: Agilent (A), DENTSPLY SIRONA (XRAY) and Exact Sciences (EXAS)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Agilent (A – Research Report), DENTSPLY SIRONA (XRAY – Research Report) and Exact Sciences (EXAS – Research Report).
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Agilent (A)
HSBC analyst Sidharth Sahoo initiated coverage with a Buy rating on Agilent today and set a price target of $180.00. The company’s shares closed last Friday at $139.64.
According to TipRanks.com, Sahoo is ranked #8559 out of 12040 analysts.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Agilent with a $171.67 average price target, a 19.0% upside from current levels. In a report issued on January 5, Evercore ISI also upgraded the stock to Buy with a $160.00 price target.
See the top stocks recommended by analysts >>
DENTSPLY SIRONA (XRAY)
Mizuho Securities analyst Steven Valiquette maintained a Hold rating on DENTSPLY SIRONA today and set a price target of $14.00. The company’s shares closed last Friday at $12.21.
According to TipRanks.com, Valiquette is a 2-star analyst with an average return of
DENTSPLY SIRONA has an analyst consensus of Hold, with a price target consensus of $13.10, which is a 4.8% upside from current levels. In a report issued on January 14, TipRanks – PerPlexity also upgraded the stock to Hold with a $13.00 price target.
Exact Sciences (EXAS)
Mizuho Securities analyst Bradley Bowers downgraded Exact Sciences to Hold yesterday and set a price target of $105.00. The company’s shares closed last Friday at $102.43.
According to TipRanks.com, Bowers is ranked #2511 out of 12040 analysts.
The word on The Street in general, suggests a Hold analyst consensus rating for Exact Sciences with a $100.50 average price target, implying a -1.8% downside from current levels. In a report issued on January 5, Evercore ISI also downgraded the stock to Hold with a $105.00 price target.
